{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:50Z","timestamp":1791357470422,"version":"4.3.1"},"reference-count":29,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,7,1]]},"abstract":"<jats:p>Objectives. Atomoxetine seems to be as effective for treating attention-deficit\/hyperactivity disorder (ADHD) when the daily dose is administered once in the morning as when the dose is divided and administered in the morning and evening. In the present study, the efficacy of atomoxetine administered once daily among children with ADHD was assessed throughout the day, including the evening and early morning. Another goal was to determine how early in treatment it was possible to discern a specific effect of the drug on ADHD symptoms.<\/jats:p><jats:p>Methods. This study was a randomized, multicenter, double-blind, placebo-controlled trial conducted at 12 outpatient sites in the United States. A total of 197 children, 6 to 12 years of age, who had been diagnosed as having ADHD, on the basis of the Diagnostic and Statistical Manual of Mental Disorders (4th ed.) criteria, were randomized to receive 8 weeks of treatment with atomoxetine or placebo, dosed once daily in the mornings. ADHD symptoms were assessed with parent and investigator rating scales. The primary outcome measure was the Attention-Deficit\/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored total score. Daily parent assessments of children's home behaviors in the evening and early morning were recorded with an electronic data entry system. This instrument measures 11 specific morning or evening activities, including getting up and out of bed, doing or completing homework, and sitting through dinner.<\/jats:p><jats:p>Results. Seventy-one percent of the children enrolled were male, 69% met criteria for the combined subtype (both inattentive and hyperactive\/impulsive symptoms), and the most common psychiatric comorbidity was oppositional defiant disorder (35%). Once-daily atomoxetine (final mean daily dose of 1.3 mg\/kg) was significantly more effective than placebo in treating core symptoms of ADHD. Mean reductions in the Attention-Deficit\/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator-Administered and Scored total score were significantly greater for patients randomized to atomoxetine, beginning at the first visit after the initiation of treatment and continuing at all subsequent visits. Both inattentive and hyperactive\/impulsive symptom clusters were significantly reduced with atomoxetine, compared with placebo. With continued treatment and dose titrations, core symptoms of ADHD continued to decrease throughout the 8-week study. Mean reductions in the daily parent assessment total scores for patients randomized to atomoxetine were superior during the first week, beginning with the first day of dosing, and were also superior at endpoint. Efficacy outcomes for the evening hours for atomoxetine-treated patients were superior to those for placebo-treated patients, as assessed with 2 different assessment scales. Decreases in the daily parent assessment morning subscores at endpoint showed a significant reduction in symptoms that lasted into the mornings. Rates of discontinuations attributable to adverse events were &amp;lt;5% for both groups. Adverse events reported significantly more frequently with atomoxetine were decreased appetite, somnolence, and fatigue.<\/jats:p><jats:p>Conclusions. Among children 6 to 12 of age who had been diagnosed as having ADHD, once-daily administration of atomoxetine in the morning provided safe, rapid, continuous, symptom relief that lasted not only into the evening hours but also into the morning hours. Atomoxetine treatment was safe and well tolerated.<\/jats:p>","DOI":"10.1542\/peds.114.1.e1","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:53:04Z","timestamp":1092444784000},"page":"e1-e8","source":"Crossref","is-referenced-by-count":239,"title":["Once-Daily Atomoxetine Treatment for Children With Attention-Deficit\/Hyperactivity Disorder, Including an Assessment of Evening and Morning Behavior: A Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1542","volume":"114","author":[{"given":"Douglas K.","family":"Kelsey","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin R.","family":"Sumner","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Casat","sequence":"additional","affiliation":[{"name":"Behavioral Health Center, Charlotte, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Coury","sequence":"additional","affiliation":[{"name":"Children's Hospital, Pediatric Clinical Trials International, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Quintana","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Science Center, New Orleans, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith E.","family":"Saylor","sequence":"additional","affiliation":[{"name":"NeuroScience, Inc, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia K.","family":"Sutton","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Gonzales","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra K.","family":"Malcolm","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kory J.","family":"Schuh","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.","family":"Allen","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,7,1]]},"reference":[{"key":"2021121006513029900_R1","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000"},{"key":"2021121006513029900_R2","doi-asserted-by":"crossref","unstructured":"Hechtman L. Assessment and diagnosis of attention-deficit\/hyperactivity disorder. Child Adolesc Psychiatr Clin N Am.\u20082000;9:481\u2013498","DOI":"10.1016\/S1056-4993(18)30102-0"},{"key":"2021121006513029900_R3","doi-asserted-by":"crossref","unstructured":"Brown RT, Borden KA. Hyperactivity at adolescence: some misconceptions and new directions. J Clin Child Psychol.\u20081986;15:194\u2013209","DOI":"10.1207\/s15374424jccp1503_1"},{"key":"2021121006513029900_R4","unstructured":"Hechtman L. Attention-deficit hyperactivity disorder. In: Hechtman L, ed. Do They Grow Out of It? Long-Term Outcomes of Childhood Disorders. Washington, DC: American Psychiatric Press; 1996:17\u201338"},{"key":"2021121006513029900_R5","unstructured":"Klein RG, Mannuzza S. The long-term outcome of the attention-deficit disorder\/hyperkinetic syndrome. In: Sagvolden T, Archer T, eds. Attention Deficit Disorder: Clinical and Basic Research. Hillsdale, NJ: Lawrence Erlbaum Associates; 1989:71\u201391"},{"key":"2021121006513029900_R6","doi-asserted-by":"crossref","unstructured":"Klein RG, Mannuzza S. Long-term outcome of hyperactive children: a review. J Am Acad Child Adolesc Psychiatry.\u20081991;30:383\u2013387","DOI":"10.1097\/00004583-199105000-00005"},{"key":"2021121006513029900_R7","doi-asserted-by":"crossref","unstructured":"Thorley G. Review of follow-up and follow-back studies of childhood hyperactivity. Psychol Bull.\u20081984;96:116\u2013132","DOI":"10.1037\/0033-2909.96.1.116"},{"key":"2021121006513029900_R8","unstructured":"Weiss G. Research issues in longitudinal studies. In: Hechtman L, ed. Do They Grow Out of It? Long-Term Outcomes of Childhood Disorders. Washington, DC: American Psychiatric Press; 1996:1\u201316"},{"key":"2021121006513029900_R9","unstructured":"Weiss G, Hechtman LT. Hyperactive Children Grown Up. 2nd ed. New York, NY: Guilford Press; 1993"},{"key":"2021121006513029900_R10","doi-asserted-by":"crossref","unstructured":"MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit\/hyperactivity disorder. Arch Gen Psychiatry.\u20081999;56:1073\u20131086","DOI":"10.1001\/archpsyc.56.12.1073"},{"key":"2021121006513029900_R11","doi-asserted-by":"crossref","unstructured":"Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry.\u20082001;40:180\u2013187","DOI":"10.1097\/00004583-200102000-00012"},{"key":"2021121006513029900_R12","doi-asserted-by":"crossref","unstructured":"Stein MA. Methylphenidate dosing: twice daily versus three times daily. Pediatrics.\u20081996;98:748\u2013756","DOI":"10.1542\/peds.98.4.748"},{"key":"2021121006513029900_R13","unstructured":"Heiligenstein J, Spencer T, Faries DE, Biederman J, Kratochvil CJ, Conners CK. Efficacy of atomoxetine vs. placebo in pediatric outpatients with ADHD. Presented at the American Academy of Child and Adolescent Psychiatry 47th annual meeting, Washington, DC, October 24\u201329, 2000"},{"key":"2021121006513029900_R14","doi-asserted-by":"crossref","unstructured":"Michelson D, Faries DE, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics.\u20082001;108(5). Available at: www.pediatrics.org\/cgi\/content\/full\/108\/5\/e83","DOI":"10.1542\/peds.108.5.e83"},{"key":"2021121006513029900_R15","doi-asserted-by":"crossref","unstructured":"Michelson D, Allen J, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry.\u20082002;159:1896\u20131901","DOI":"10.1176\/appi.ajp.159.11.1896"},{"key":"2021121006513029900_R16","unstructured":"Newcorn J. Efficacy trials of atomoxetine for ADHD in children, adolescents, and adults. Presented at the American Academy of Child and Adolescent Psychiatry 49th annual meeting, San Francisco, CA, October 22\u201327, 2002"},{"key":"2021121006513029900_R17","doi-asserted-by":"crossref","unstructured":"Spencer TJ, Biederman J, Wilens TE, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry.\u20081998;155:693\u2013695","DOI":"10.1176\/ajp.155.5.693"},{"key":"2021121006513029900_R18","doi-asserted-by":"crossref","unstructured":"Swanson J, Gupta S, Guinta D, et al. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther.\u20081999;66:295\u2013305","DOI":"10.1016\/S0009-9236(99)70038-X"},{"key":"2021121006513029900_R19","doi-asserted-by":"crossref","unstructured":"Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children\u2014Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry.\u20081997;36:980\u2013988","DOI":"10.1097\/00004583-199707000-00021"},{"key":"2021121006513029900_R20","doi-asserted-by":"crossref","unstructured":"DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, NY: Guilford Press; 1998","DOI":"10.1037\/t00680-000"},{"key":"2021121006513029900_R21","doi-asserted-by":"crossref","unstructured":"Faries DE, Yalcin I, Harder D, Heiligenstein JH. Validation of the ADHD rating scale as a clinician administered and scored instrument. J Attention Disord.\u20082001;5:39\u201347","DOI":"10.1177\/108705470100500204"},{"key":"2021121006513029900_R22","doi-asserted-by":"crossref","unstructured":"Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: United States Department of Health, Education, and Welfare; 1976","DOI":"10.1037\/e591322011-001"},{"key":"2021121006513029900_R23","doi-asserted-by":"crossref","unstructured":"Conners CK. Conners' Rating Scales, Revised. Toronto, Canada: Multi-Health Systems; 1997","DOI":"10.1037\/t81067-000"},{"key":"2021121006513029900_R24","unstructured":"SAS Institute. SAS\/STAT Software: Changes and Enhancements Through Release 6.12. 4th ed. Cary, NC: SAS Institute; 1997"},{"key":"2021121006513029900_R25","unstructured":"Allen AJ, Michelson D, Kelsey D, et al. Once- or twice-daily atomoxetine treatment in children and adolescents with ADHD: does it make a difference? Presented at the Society of Biological Psychiatry 58th annual meeting, San Francisco, CA, May 15\u201317, 2003"},{"key":"2021121006513029900_R26","unstructured":"Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ.\u20082001;165:1475\u20131488"},{"key":"2021121006513029900_R27","unstructured":"Kratochvil C. Long-term safety of atomoxetine in children treated for ADHD. Presented at the American Academy of Child and Adolescent Psychiatry 49th annual meeting, San Francisco, CA, October 22\u201327, 2002"},{"key":"2021121006513029900_R28","unstructured":"Wernicke JF, Kratochvil C, Milton D, et al. Long-term safety of atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder. Presented at the American Psychiatric Association 155th annual meeting, Philadelphia, PA, May 18\u201323, 2002"},{"key":"2021121006513029900_R29","doi-asserted-by":"crossref","unstructured":"Kent MA, Camfield CS, Camfield PR. Double-blind methylphenidate trials. Arch Pediatr Adolesc Med.\u20081999;153:1292\u20131296","DOI":"10.1001\/archpedi.153.12.1292"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/1\/e1\/1005840\/zpe007040000e1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/1\/e1\/1005840\/zpe007040000e1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:38:19Z","timestamp":1682746699000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/1\/e1\/64796\/Once-Daily-Atomoxetine-Treatment-for-Children-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,7,1]]},"published-print":{"date-parts":[[2004,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.114.1.e1","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,1]]}}}